Overview

• AUN combines Proteus mirabilis (A-gyo) and Rhodopseudomonas palustris (UN-gyo) into a dual-species consortium designed for tumor targeting.
• The therapy induces selective vascular collapse and direct cancer cell killing to eradicate tumors in both mouse and human models without relying on immune cells.
• Tumor metabolites trigger A-gyo filamentation and shift the intratumoral ratio from approximately 3:97 to 99:1, amplifying antitumor potency.
• UN-gyo serves as a regulatory partner, suppressing overall pathogenicity while enhancing tumor-specific cytotoxicity.
• Preclinical studies report high biocompatibility with minimal side effects, and the research team is preparing a startup to launch clinical trials by 2031.